Skip to main content
. 2021 Jan 19;16(1):e0245526. doi: 10.1371/journal.pone.0245526

Fig 5. Efficacy of VMAT2 and COMT inhibitor in neuroblastoma cell lines.

Fig 5

(A) IMR-32 (MYCN-cluster with MYCN amplification) and (B) NB-69 (ATRX-cluster with high SCL18A2 [VMAT2] expression) cells were examined in triplicate. Cells were treated with DMSO, GZ-793A (VMAT2 inhibitor, Sigma #SML0851), or Tolcapone (COMT inhibitor, Sigma #SML0150) and examined cell proliferation in each condition by using Cell Counting Kit-8 (Sigma, #96992) at 24, 48, 72, 96 hours after treatment. Mean (± SEM) cell proliferation rate was calculated by comparing detected absorbance before and after treatment.